China’s Early Strategy: Pay to Play

Early in its COVID-19 fight, China was dogged by testing shortages that made getting diagnosed akin to “winning the lottery”—though many tests delivered false negatives.
What was to blame? “Secrecy and cronyism” at the top disease control agency, AP reports.
Obscure companies paid China’s CDC for information and distribution rights and produced faulty kits, as the CDC tried to stop other testing by other providers.
Amid these actions, not a single new case was reported from January 5–17, hampering chances to warn the public of the virus’s spread and enact restrictions.

Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top